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Cardiovascular disease (CVD) is the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). 
The current analysis expands the knowledge on atherogenic lipid profiles in NAFLD by modeling changes in low-
density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in a prospectively enrolling real-life study cohort to 
inform physicians on the cardiovascular (CV) event risk based on these changes. A total of 304 patients with histo-
logically confirmed NAFLD were included (mean age, 52  years; equal sex distribution). Of these, 129 (42.4%) patients 
exhibited a NAFLD activity score ≥4 and 186 (61.2%) had at least intermediate fibrosis ≥F2. The median TC levels 
were 209  mg/dL (interquartile range [IQR], 183, 239), LDL-C 131  mg/dL (IQR, 103, 152), and high-density lipopro-
tein cholesterol (HDL-C) 45  mg/dL (IQR, 38, 52). Only 16.9% of patients received lipid-lowering therapy. According 
to the LDL/HDL ratio, 69 (23.7%) patients exhibited a high CV risk. The 10-year CV event risk according to the 
Framingham risk score (FRS) was low in 91 (41.2%), intermediate in 59 (26.7%), and high in 71 (32.1%) patients and 
higher in the ≥F2 NAFLD population. A moderate increase in LDL-C levels by 20  mg/dL led to a transition of 20% 
of patients into the high-risk group when assessing the LDL/HDL ratio. According to the FRS, 6 (2.7%) patients 
moved from low to intermediate and 11 (4.9%) from intermediate to high CV risk. Conclusion: Patients with NAFLD 
exhibit a substantial CV event risk and are frequently undertreated with lipid-lowering medication. Moderate increases 
in LDL-C would result in worsening of the CV event risk in approximately 7.8% of all patients without a history of 
CVD. (Hepatology Communications 2019;0:1-10).
Globally, nonalcoholic fatty liver disease (NALFD) is the most common liver disease, with an estimated prevalence of 24% world-
wide. An increasing incidence has been predicted 
based on the high prevalence of associated risk fac-
tors in Europe.(1) NAFLD constitutes a progressive 
disease spectrum encompassing noninflammatory 
steatosis (nonalcoholic fatty liver [NAFL]), hepatitis 
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(nonalcoholic steatohepatitis [NASH]), and end-
stage liver disease, with associated complications.(2) 
In addition to the individual disease burden, the large 
number of patients with NAFLD who are at risk to 
develop progressive liver disease pose societal and 
economic challenges for health care systems.(3) In 
2013, end-stage liver disease related to NAFLD was 
the second most common reason for liver transplan-
tation in the United States.(4) Beyond liver-associated 
mortality, patients with NAFLD exhibit impaired 
cardiovascular (CV) fitness(5) and increased overall 
mortality, with the primary cause of death being CV 
events.(6) In a recent analysis, NAFLD was associ-
ated with incidental nonfatal coronary heart disease 
and all-cause mortality events, with a hazard ratio of 
1.43 after adjustment for traditional risk factors.(7) 
In observational NAFLD cohorts with long-term 
follow-up, there is an excess of CV events and mor-
tality.(8) These clinical data and additional transla-
tional studies support the view that NALFD is an 
inflammatory multisystem disease that affects CV 
health.(9,10) The mortality risk increases in patients 
with intermediate and advanced fibrosis, and thus this 
subgroup has been defined as the target population 
for liver-directed therapies that are currently devel-
oped in phase 3 trials.(11) For this reason, regulatory 
authorities have accepted histologic surrogates for 
conditional drug approval.(12) One of these endpoints 
(improvement of fibrosis by at least one point without 
worsening of steatohepatitis) was recently met in the 
trial Randomized Global Phase 3 Study to Evaluate 
the Impact on NASH With Fibrosis of Obeticholic 
Acid Treatment (REGENERATE), which is the 
first study to achieve this primary endpoint.(13) The 
REGENERATE study explored the first-generation 
steroidal farnesoid X receptor (FXR) agonist obeti-
cholic acid (OCA) in 931 patients over 18 months.(13) 
Although hepatic fibrosis improved in the group 
receiving 25  mg of OCA in 23.1% of the patients, 
this also led to an increase in low-density lipoprotein 
cholesterol (LDL-C) by approximately 20%. This was 
comparable to data observed in the phase 2 Farnesoid 
X Receptor Ligand Obeticholic Acid in NASH 
Treatment Trial (FLINT)(14) and a healthy volunteers 
study.(15) The effect on lipids relates back to an FXR-
specific effect leading to decreasing LDL-C receptor 
and increasing transfer cholesteryl ester transfer pro-
tein, thus reducing high-density lipoprotein choles-
terol (HDL-C) and increasing LDL-C levels.(16)
Although improving hepatic fibrosis could trans-
late into improved overall survival in patients with 
NAFLD (an endpoint that is currently still under 
investigation in the ongoing phase 3 trials), the role of 
increasing LDL-C can counteract the potential ben-
efits. Ample evidence supports that lowering LDL-C 
in patients with CV risk is beneficial.(17) Therefore, 
we analyzed the CV risk profile in patients with his-
tologically confirmed NAFLD and grouped them 
according to the most commonly used and rapidly 
available surrogate risk score of cardiovascular disease 
(CVD) and mortality. Once a medical treatment for 
NAFLD is approved, safety will be of high priority, 
and the current analysis provides data on changes in 
the relative CV event risk in biopsy-proven NAFLD 
cases based on a model accounting for LDL-C and 
total cholesterol (TC).
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Patients and Methods
patient CoHoRt anD etHiCal 
ConsiDeRations
A total of 304 adult patients with biopsy-proven 
NAFLD were included in this prospectively enroll-
ing protocol, which is part of the European NAFLD 
registry, between December 2013 and January 2019. 
Prior to inclusion, informed consent was obtained at 
the outpatient clinic of the University Medical Center 
Mainz, Germany. Alcohol use was assessed on clini-
cal grounds and random ethyl glucuronide measure-
ments in the urine. Patients with coexisting or other 
liver disease, including chronic or acute viral hepa-
titis, cholestasis, and autoimmune liver disease, were 
excluded as were causes of secondary steatohepatitis, 
including steatogenic medications. Diabetes mellitus, 
hypertension, hyperlipidemia, and metabolic syndrome 
were defined according to the definitions of the Joint 
Scientific Statement for Harmonizing the Metabolic 
Syndrome.(18) Laboratory test results were obtained 
within 30 days of liver biopsy. Samples for analyses of 
lipids were obtained in patients after overnight fast-
ing. Liver biopsies were performed by laparoscopy or 
transcutaneously and scored by a liver histopathologist 
experienced in NAFLD (B.K.S.). Patients with liver 
biopsies  <  10  mm in length were excluded. NASH 
was diagnosed and subsequently scored according to 
the NASH Clinical Research Network criteria.(19)
patient Consent anD etHiCal 
ConsiDeRation
The study was conducted according to the ethical 
guidelines of the 1975 Declaration of Helsinki (6th 
revision, 2008). The study protocol was approved by the 
ethics committee of the regional medical association of 
Rhineland-Palatinate (ethical proposal no. 873.199.10 
[7208]).
suRRogate sCoRes oF CV RisK
The Framingham risk score (FRS) was used to 
predict incident CVD. FRS combines sex, age, TC, 
HDL-C, presence of diabetes, systolic blood pressure, 
treatment for hypertension, and current smoking status, 
specifying the 10-year CVD risk in patients without 
a known CVD.(20) We assigned the risk estimate of a 
30-year-old to all individuals between the age of 18 and 
29 years. In addition, the LDL/HDL ratio(21) and TC, 
LDL-C, triglycerides, and low HDL-C concentrations 
were analyzed according to established cutoffs.(22)
statistiCal analysis
Quantitative data are expressed as median with 
interquartile range (IQR). Pairwise comparisons for 
quantitative variables were performed with an unpaired 
t test or the Mann-Whitney U test. Categorical vari-
ables are given as frequencies and percentages, respec-
tively, and for the comparison of two or more patient 
groups, a chi-square test was applied. Data analysis 
was exploratory, and no adjustments for multiple test-
ing were performed. For all tests, a 0.05 level to define 
statistically relevant deviations from the respective 
null hypothesis was applied. However, due to the large 
number of tests, P values should be interpreted with 
caution and in connection with effect estimates. Data 
were analyzed using IBM SPSS Statistics, version 




A total of 304 patients with histologically con-
firmed NAFLD were included in this analysis. Half of 
the patients were men, with a median age of 52 years 
(IQR, 39, 59). Metabolic risk factors were highly 
prevalent in the population, with 60.9% exhibiting 
arterial hypertension and 36.2% diabetes mellitus type 
2. Median body mass index (BMI) was 31.4  kg/m2 
(IQR, 27.8, 35.5), and only 26 (8.6%) patients were 
not overweight (BMI, 19-25 kg/m2). Of the patients, 
12.8% were current smokers, and an additional 18.8% 
reported a history of smoking. Standard laboratory 
assessment is summarized in Table 1. Median LDL-C 
levels were 131 mg/dL (IQR, 103, 152) in the entire 
cohort, with 67 (22%) patients exhibiting elevations 
>155  mg/dL. The distribution of the lipid profile in 
relation to the underlying disease activity and his-
tologic stage of liver disease is shown in Table 2. 
Importantly, only 16.1% of the entire cohort received 
lipid-lowering drugs at the time of referral, and a 
total of 16 (5.3%) patients had a history of coronary 
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heart disease. CV events in relatives before the age 
of 60 were present in 40 (13.2%) patients (Table 1). 
Consumption of low degrees of alcohol, compatible 
with NAFLD, was reported by 45.7% of patients, 
whereas 13.5% reported no alcohol and 40.8% prior 
alcohol consumption. There was no significant influ-
ence of alcohol consumption on lipid levels when 
compared to abstainers (P value not significant).
suRRogates oF CVD anD  
all-Cause moRtality in  
patients WitH HistologiCally 
DeFineD naFlD
Decreasing LDL-C and increasing HDL-C 
are associated with regression of coronary 
atherosclerosis.(17) To assess the CV risk, the num-
ber of patients exceeding an LDL/HDL ratio of 
>3.5 was determined. Although LDL-C thresh-
olds have been abandoned, the LDL/HDL ratio 
has historically been defined for primary and sec-
ondary prevention of CV events.(23) A total of 235 
(76.3%) patients exhibited a low risk (cutoff, ≤3.5), 
whereas 69 (23.7%) of the patients had a high risk 
for a CV event (cutoff, >3.5) (Table 3). According 
to the LDL/HDL ratio, significantly fewer patients 
with NASH were grouped as high risk compared to 
NAFL (18.5% vs. 26.8%; P  =  0.040). There was no 
significant difference in the number of patients with 
an LDL/HDL ratio >3.5 when comparing NAFLD 
activity score (NAS) <4 with NAS ≥4 (26.3% vs. 
17.8%; P = 0.082) (Table 3).
taBle 1. DemogRapHiCs anD CliniCal CHaRaCteRistiCs
Variable*
All Patients Patients With NAS ≥4 Patients With F ≥2
N = 304 n = 129 n = 186
Age, years 52 (39, 59) 52 (38, 59) 54 (39, 60)
Male sex, n 156 (51.3) 62 (48.1) 97 (52.2)
Current smoker, n† 39 (12.8) 21 (16.3) 30 (16.1)
History of smoking, n† 57 (18.8) 24 (18.6) 37 (19.9)
ALT, U/L 72 (48, 109) 87 (57, 122) 80 (52, 120)
AST, U/L 52 (38, 75) 63 (47, 87) 62 (42, 85)
CVD Total, n 30 (9.9) 11 (8.5) 20 (10.8)
Coronary heart disease, n 16 (5.3) 6 (4.7) 11 (5.9)
History of stroke, n 14 (4.6) 5 (3.9) 9 (4.8)
CVD in family history 40 (13.2) 17 (13.2) 24 (12.9)
Diabetes type 2, n 110 (36.2) 59 (45.7) 87 (46.8)
Arterial hypertension, n 185 (60.9) 82 (63.6) 129 (69.4)
Cholesterol,‡ mg/dL 209 (183, 239) 205 (172, 236) 205 (177, 236)
Triglycerides,§ mg/dL 154 (115, 215) 168 (119, 230) 164 (120, 214)
HDL-C, mg/dL 45 (38, 52) 45 (38, 52) 44 (36, 52)
LDL-C, mg/dL Total 131 (103, 152) 126 (99, 149) 128 (99, 148)
Lipid-lowering drugs Total, n 49 (16.1) 24 (18.6) 37 (19.9)
Statins, n 43 (14.1)
Other, n 6 (2.0)
NASH 151 (49.7) 113 (87.6) 124 (66.7)
Cirrhosis 40 (13.2) 18 (14.0) 40 (21.5)
NAS Median 3 (2, 4) 4 (3, 5)
≥4, n 129 (42.4) 129 (100) 109 (58.6)
Fibrosis ≥2 186 (61.2) 109 (84.5) 186 (100)
*Data are expressed as medians and IQRs or as frequencies and percentages.
†Data were available in 234 patients.
‡Data were available in 289 patients.
§Data were available in 288 patients.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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Absolute cutoffs for cholesterol are frequently used 
in clinical routine and practice. Within the Framingham 
Heart Study, a >2.25-fold risk of atherosclerotic CVD 
and mortality over 35 years was observed for TC (>240 
vs. <165 mg/dL), LDL-C (>155 vs. <90 mg/dL), and 
HDL-C (<40 vs. >70  mg/dL).(22) Patients with sig-
nificant liver disease, defined as NAS ≥4 and fibrosis 
(F) score ≥F2, exhibited TC >240  mg/dL in 21.7%, 
LDL-C >155 mg/dL in 18.3%, and HDL < 40 mg/dL 
in 32.1% (Table 2).
The FRS is most commonly used to estimate 
the incident 10-year risk of nonfatal and fatal arte-
rial CV events or CVD mortality.(24) The FRS was 
calculated in 221 patients without prior CVD.(20) A 
total of 51 patients were excluded for incomplete data, 
mostly missing systolic blood pressure. According to 
the FRS, 32.1% of the patients exhibited a high risk, 
with a predicted CV risk >20% in the next 10 years. 
At the other end of the CV risk spectrum, 41.2% of 
the patients were assigned to the low-risk category 
(Table 4). When comparing patients with at least 
intermediate fibrosis on liver biopsy (≥F2) to patients 
with absent or early fibrosis (≤F1), the ≥F2 group had 
a significantly higher 10-year CVD event risk accord-
ing to the FRS (Table 3). When analyzing patients 
with relevant liver disease on biopsy defined by an 
NAS ≥4 and ≥F2 (n  =  88, 39%), the following CV 
risk categories were observed: 15.6% (95% confidence 
interval [CI], 13.6, 18.0) 10-year CVD according 
to the FRS (Table 3), 18.3% high risk according to 
the LDL/HDL ratio (Table 3), and >2.25-fold risk 
of atherosclerotic CV and mortality over 35  years 
according to either TC, LDL-C, or HCL-C in 
33.2%. Interestingly, when analyzing the group with 
taBle 2. lipiD pRoFiles in patients WitH DiFFeRent HistologiC gRaDes
Variable* NAS <4 NAS ≥4 F ≥2 F <2 NAS ≥4 and F ≥2
Cholesterol 212 (186, 243) 205 (172, 236) 205 (177, 236) 215 (187, 248) 205 (174, 236)
>240 mg/dL 42 (25.6%) 27 (21.6%) 36 (20.2%) 33 (30.0%) 23 (21.7%)
<165 mg/dL 23 (14.0%) 24 (19.2%) 32 (18.0%) 15 (13.6%) 19 (17.9%)
LDL-C 135 (108, 156) 126 (99, 149) 128 (99, 148) 136 (111, 163) 126 (98, 149)
>155 mg/dL 44 (25.1%) 23 (17.8%) 33 (17.7%) 33 (28.2%) 20 (18.3%)
<90 mg/dL 23 (13.1%) 22 (17.1%) 32 (17.2%) 13 (11.1%) 20 (18.3%)
HDL-C 44 (38, 52) 45 (38, 52) 44 (36, 52) 46 (41, 52) 45 (38, 52)
>70 mg/dL 12 (6.9%) 3 (2.3%) 10 (5.4%) 5 (4.3%) 3 (2.8%)
<40 mg/dL 50 (28.6%) 42 (32.6%) 67 (36.0%) 25 (21.4%) 35 (32.1%)
Triglycerides 149 (111, 210) 168 (119, 230) 164 (120, 214) 149 (106, 225) 159 (118, 229)
Cholesterol >240 mg/dL + LDL-C 
>155 mg/dL + HDL-C <40 mg/dL
3 (1.8%) 6 (4.8%) 6 (1.7%) 3 (2.7%) 4 (3.8%)
*Data are expressed as medians and IQRs or as frequencies and percentages.
taBle 3. CV eVent RisK aCCoRDing to tHe FRs anD lDl/HDl Ratio in patients WitH DiFFeRent 
HistologiC gRaDes
Variable n
10-year CVD Risk  
According to FRS* P Value n
High Risk According  
to LDL/HDL* P Value
Total cohort (N) 221 13.7 (6.3, 25.3) 304 69 (23.7%)
Advanced fibrosis (≥F2) 143 15.9 (7.3, 28.5) 0.002 186 41 (22.0%) 0.703
Early fibrosis (<F2) 78 10.0 (4.4, 18.5) 118 28 (23.7%)
NAS ≥4 103 13.7 (5.3, 25.3) 0.711 129 23 (17.8%) 0.082
NAS <4 118 13.7 (6.7, 24.8) 175 46 (26.3%)
NASH 125 15.6 (6.3, 28.5) 0.099 151 28 (18.5%) 0.040
NAFLD 96 12.5 (5.6, 21.5) 153 41 (26.8%)
Advanced fibrosis + NAS ≥4 88 15.6 (5.4, 27.7) 0.660 109 20 (18.3%) 0.176
Others 133 13.7 (6.3, 23.2) 195 49 (25.1%)
*Data are expressed as medians and IQRs or as frequencies and percentages.
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less severe liver disease, defined by NAS ≤ 3 and F1 
or F0, CVD risk surrogates according to the FRS and 
the LDL/HDL ratio were comparable to patients 
with advanced disease (Table 3).
moDeling oF tHe CV RisK in 
patients WitH naFlD anD 
inCReasing lDl-C
Recently, the REGENERATE study investigated 
the effect of the FXR agonist OCA in NASH and 
reported positive results meeting its primary endpoint. 
While OCA improved hepatic fibrosis in 23.1% of 
patients, this treatment also increased LDL-C by 
approximately 20  mg/dL. To explore the impact of 
this increase in LDL-C and consequently in TC 
in patients with histologically confirmed NAFLD, 
we modeled a rise in LDL-C by 20  mg/dL in our 
patients and used the FRS to assess changes in the 
CV risk profile (Fig. 1). A moderate increase of 
LDL-C by 20  mg/dL resulted in 20.7% (n  =  63) of 
patients to move from a low to a high CV risk cate-
gory based on the LDL/HDL ratio (Table 5). When 
modeling the FRS and using an increase of TC by 
20 mg/dL, this resulted in a median increase of 1.9% 
for the 10-year CVD event risk in the entire group 
and the number needed to harm of 53 (no increase, 
13.7% [95% CI, 14.0, 16.6] vs. TC increase, 15.6% 
[95% CI, 14.7, 17.4]). In patients with significant liver 
disease, defined by NAS ≥4 and ≥F2, this effect did 
not differ from the entire cohort. According to the 
FRS, 6 (2.7%) patients moved from low to interme-
diate and 11 (4.9%) from intermediate to high CV 
risk (Table 6). When modeling an increase of TC and 
LDL-C by 20 mg/dL, 41.5% of patients exhibited a 
TC >240 mg/dL and 45.1% an LDL-C >155 mg/dL.
The current American Association of Clinical 
Endocrinologists (AACE) categorizes patients into 
extreme, very high, high, moderate, and low risk of a 
subsequent CV event and defines LDL-C target cor-
ridors.(25) In the entire cohort, 33.2% (101/304) were 
very high risk, mainly based on established CVD and 
diabetes with one additional risk factor, and 37.5% 
(114/304) were high risk, mainly defined through 
two risk factors, or the presence of diabetes.(25) When 
analysing all patients according to FRS categories, 
only 13/101 in the very high-risk and 34/114 in 
Fig. 1. Modulation of the incident 10-year CV risk using the FRS 
in patients with histologically confirmed NAFLD and early (<F2) 
versus significant (≥F2) fibrosis.
taBle 5. sHiFt taBle FoR lDl/HDl Ratio in 
tHe total CoHoRt
Baseline risk
Risk From Treatment (LDL + 20 mg/dL)
Low risk High risk
Low risk 172 (56.6%) 63 (20.7%)
High risk 0 69 (22.7%)
Data are expressed as frequencies and percentages.
taBle 4. FRs gRoups in tHe total CoHoRt
n = 221 Low Risk (≤10% 10-Year CVD Risk) Intermediate Risk (10%-20% 10-Year CVD Risk) High Risk (>20% 10-Year CVD Risk)
Male 50 (22.6%) 25 (11.3%) 39 (17.6%)
Female 41 (18.6%) 34 (15.4%) 32 (14.5%)
Total cohort 91 (41.2%) 59 (26.7%) 71 (32.1%)
Data are expressed as frequencies and percentages.
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the high-risk groups were below the recommended 
LDL-C of  <70 mg/dL, or  <100 mg/dL, respectively. 
The remaining 88/101 patients in the very high and 
80/114 in the high-risk groups that were above the 
recommended LDL-C level had a low rate of sta-
tin prescription, with 24 of the 88 and 21 of the 80 
patients being on statins.
Discussion
CV risk factors are highly prevalent in patients 
with NAFLD, and CV mortality contributes signifi-
cantly to their overall loss of life time.(26) It has been 
estimated that 5% to 10% of patients with NAFLD 
die from CVD, and patients with NAFLD exhibit a 
2-fold increased risk of CVD.(27,28) A meta-analysis 
exploring more than 17,000 patient-years observed 
CVD to be the leading cause of mortality in patients 
with NAFLD.(6) In a recent exploration of the 
National Health and Nutrition Examination Survey 
III, a 42% higher overall mortality rate and doubling 
of the risk of CV mortality for patients with NAFLD 
were observed.(29) This risk was even higher in a 
robust meta-analysis that included data of 16 obser-
vational studies with a total of 34,043 patients. Here, 
the presence of NAFLD related to an increase of 64% 
for fatal or nonfatal CVD, and this risk was higher 
in patients with more advanced fibrosis or NASH 
inflammation.(30) The number of patients with a his-
tory of CVD in the current study was relatively low 
(5.3%) compared to other cohorts that ranged from 
18% in a population-based cohort(31) and 9.3% in a 
cohort with liver biopsy.(27) Additionally, by exploring 
taBle 6. sHiFt taBle FoR tHe FRs
A total of 221 patients were analyzed according to the FRS and classified as low (1%-9.9%), medium (10%-19.9%), and high (≥20%) risk. 
By modeling a 20-mg/dL increase of TC, 2.7% (6/221) of patients went from a low to a medium and 4.9% (11/211) from a medium to a 
high CVD risk according to the FRS. Left column shows baseline CVD risk category; top column modeled CVD risk category.
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a referral cohort at an outpatient hepatology center, 
patients with recent CV events were likely not to be 
included because treatment of their underlying CVD 
was a priority at that time. This is also reflected by 
the absence of patients in the extreme atherosclerotic 
CVD risk categories according to the AACE in our 
study cohort.(25) Nonetheless, 32.2% of all patients had 
a high 10-year risk for development of CVD events 
according to the FRS, and we report these figures for 
the first time for a German cohort. When interpret-
ing these data, the descriptive nature must be taken 
into account and the causality remains to be proven. 
Nonetheless, there is increasing evidence indicating 
a link between NAFLD, and especially NASH, and 
deterioration of atherogenic dyslipidemia, systemic 
inflammation, insulin resistance, and thrombogenic 
factors, which can all increase the risk for incident 
CVD.(32,33)
analysis oF moRtality
Currently, several phase 3 trials are underway to 
investigate the benefit of liver-directed therapy to 
induce the resolution of steatohepatitis or regression 
of fibrosis defined by liver histology. There is ample 
evidence that advanced fibrosis leads to excess mor-
tality related to CVD and nonhepatic malignancy.(6) 
Additionally, data from the literature suggest that 
resolution of steatohepatitis improves endothelial dys-
function and lowers CVD risk.(32) However, the long-
term benefit and, in particular, effects on total mortality 
remain to be shown. Any pharmacologic agent used 
for the treatment of NAFLD is likely to be a long-
term treatment, and therefore safety profiles will have 
to be beneficial in the overall assessment. In this con-
text, the increase of LDL-C and TC that is observed 
from FXR agonists is worrisome if these translate 
into an increased CV risk. Although an atherogenic 
potential is of less concern in most patients with pri-
mary biliary cholangitis (an indication for which there 
are approved FXR agonists available), the relevance 
of LDL-C and TC increase in NAFLD can only be 
assessed through long-term follow-up. The recently 
reported phase 3 trial using OCA in NAFLD showed 
a 11.2% greater benefit from OCA in achieving fibro-
sis regression of ≥1 stage at 18  months compared to 
placebo.(13) Importantly, the treatment group experi-
enced an increase of TC and LDL-C by 20  mg/dL 
on average within the first weeks.(13) The increase 
was transient and counterbalanced by the protocol- 
initiated use of statins.
The current study highlights that 32.1% of all 
patients with biopsy-proven NAFLD in this German 
cohort exhibit a high (>20%) risk for developing a 
CV event in the next 10 years according to the FRS. 
In the subgroup of patients with significant liver dis-
ease, defined as NAS ≥4 and ≥F2, 35.2% exhibit a 
high risk. When modeling a TC or LDL-C increase 
of 20  mg/dL from a hypothetical drug, this led to a 
1.9% increase of the median CV event risk. In total, 
7.6% of patients changed their FRS risk category from 
low to medium or medium to high. Although these 
numbers seem to be low, a total of 32.5% of patients 
were considered at high risk of developing a CV event 
in the next 10  years, and the inability to lower their 
LDL-C with statins into the target range according 
to AACE guidelines could translate into increased 
mortality. Therefore, once an FXR agonist for the 
treatment of NASH has been approved, the individ-
ual assessment of the CV risk before the initiation of 
liver-directed therapy could become important. If the 
FXR-mediated effect occurs transiently and LDL-C 
target levels can be reached, the addition of a liver- 
directed drug will potentially further add to the benefit 
for the patient. Importantly, second-generation non-
steroidal FXR agonists that are currently explored in 
phase 2 trials could overcome these limitations because 
their safety profile and effects on lipids seem to be 
less pronounced. The limitations of FXRs in patients 
with high-risk CVD could also be potentially over-
come by using combination therapies of metabolically 
active anti-inflammatory and antifibrotic compounds, 
allowing for adjusting the dose of the steroidal FXR or 
counterbalancing the metabolic adverse effects.
One major finding in the current study is that only 
a minority of patients received statin therapy. This 
also held true for patients in the very high and high 
CVD risk categories who did not reach their AACE-
recommended LDL-C goals. This is troublesome 
because there is excellent evidence supporting the use of 
statins to decrease overall mortality in patients without 
prior CV events.(34) The underlying causes are likely 
multicausal. Idiosyncratic hepatotoxicity is among the 
main concerns, and it can be severe,(35) although it 
occurs in very few cases. Thus, elevated liver function 
tests can be a trigger leading to the discontinuation or 
posing a barrier to initiating treatment with statins in 
the examined cohort. Importantly, most idiosyncratic 
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drug injury patterns were associated with a choles-
tatic laboratory profile, in particular when using highly 
potent statins, for example, atorvastatin.(35) Thus, close 
monitoring and education of prescribers can help to 
distinguish liver injury from underlying NAFLD and 
idiosyncratic drug-induced liver injury. Beyond the 
CVD risk, statins have been attributed to a favor-
able effect on hepatocellular carcinoma incidence in a 
case-control study,(36) and thus their use can be benefi-
cial from both a liver and CVD perspective. Additional 
measures to improve the CV risk could be the addition 
of omega n-3 fatty acid supplements that were recently 
shown to decrease CV risk.(37)
Our study has limitations. First, the current analysis 
enrolled patients who were referred to a tertiary out-
patient clinic for evaluation of liver disease, thus intro-
ducing a selection bias with weight on more advanced 
patients. Still, the cohort was fairly balanced, with 
49.7% of the patients exhibiting NASH and an equal 
distribution of fibrosis stages.(38) Additionally, the 
implementation of a prospective study protocol within 
the scope of the European NAFLD registry ensured 
standardized workup and comparability to published 
cohorts.(38) A second limitation is the inability to pre-
dict the CVD event risk using the FRS in 51 patients, 
mostly due to missing data.
In conclusion, our study explores a biopsy-proven 
German NAFLD cohort and classifies them accord-
ing to their CV event risk. The overall CV risk is high; 
however, only a minority of patients received statin 
therapy. Additionally, the used model suggested that 
a small but potentially relevant risk increase in the 
FRS occurs if FXR-based therapy leads to increases 
in LDL-C. Therefore, management of CV risk is 
likely to be center stage in the complex management 
of patients with NAFLD over the upcoming years, 
especially when liver-directed drugs become available.
Acknowledgment: We thank the patients who partici-
pated in the study.
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